TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Ascentage Pharma
ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment

Ascentage Pharma presented updated clinical trial data for Olverembatinib, showing promising efficacy in treating chronic myeloid leukemia patients who failed previous treatments, with 76.7% complete cytogenetic response rate and deepening molecular responses over time.

Insights
TAK   neutral

Has signed an exclusive option agreement for global rights to Olverembatinib outside of certain Chinese territories